Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 2 2Phase 1/2 2

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 10Genitourinary 10Dermatologic 8Head & Neck 6Gynecologic 6Gastrointestinal 6CNS 3Breast 3Sarcoma 2Other solid neoplasm 2Lymphoid 2Tumor-Agnostic 1Plasma cell 1

Conditions

Mycosis Fungoides 1Lymphoma 1

Interventions

Rituximab 169Cyclophosphamide 158fludarabine 76Lenalidomide 73Vincristine 70fludarabine phosphate 63Etoposide 59Doxorubicin 56Prednisone 54venetoclax 49Cytarabine 48Dexamethasone 43Filgrastim 39Peripheral Blood Stem Cell Transplantation 38Methotrexate 38Bendamustine Hydrochloride 38ibrutinib 37obinutuzumab 36Gemcitabine 31pembrolizumab 27Melphalan 27Bortezomib 27Alemtuzumab 25Radiotherapy 23Nivolumab 21Carboplatin 21Tacrolimus 20Granulocyte Colony-Stimulating Factor 20Busulfan 20Whole-Body Irradiation 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × cemiplimab × Lymphoid × Clear all
NCT03769181 2025-09-23

A Study of Isatuximab-based Therapy in Participants With Lymphoma

Sanofi

Phase 1/2 Terminated
58 enrolled 37 charts
Lymphoid

Lymphoma

NCT05538988 2025-06-27

BIOSELECT

AHS Cancer Control Alberta

Phase 1/2 Withdrawn
Lymphoid

Mycosis Fungoides

Data powered by HemOnc (CC BY 4.0) Colophon âš¡